Advertisement

Current Cardiology Reports

, 21:162 | Cite as

Management of Pulmonary Arterial Hypertension in the Pediatric Patient

  • Jordan E. Ezekian
  • Kevin D. HillEmail author
Congenital Heart Disease (RA Krasuski, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Congenital Heart Disease

Abstract

Purpose of Review

Pediatric pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality. Herein we review the diagnosis and classification for pediatric PAH and detail the current therapeutic options available for use in the pediatric PAH population.

Recent Findings

Classification and treatment of pediatric PAH is guided by adult criteria and treatment algorithms, yet the distribution of factors contributing to PAH in children differs significantly from that seen in adults. It is necessary to understand these differences in order to appropriately tailor therapy to the needs of the child or adolescent. An expanding array of targeted PAH drugs are now approved for use in adults, and many of these drugs are used “off-label” to treat children and adolescents with PAH. Use of these novel therapies has coincided with marked improvement in outcomes, suggesting significant benefit. However, because most of these drugs have not been studied in rigorous randomized, controlled trials in children, it is critical that physicians understand their mechanisms of action, potential benefits, and safety profiles.

Summary

Pediatric PAH outcomes have improved substantially in the modern era, coinciding with the “off-label” use of targeted PAH drugs in children and adolescents. Ideally, care should be provided at centers with specialized expertise in the diagnosis and treatment of pediatric PAH by providers who understand the appropriate diagnostic algorithms, classification schemes, and treatment approaches.

Keywords

Pediatric pulmonary arterial hypertension Pulmonary hypertension Phosphodiesterdase-5 inhibitors Endothelin receptor antagonists Nitric oxide Prostacyclins 

Notes

Compliance with Ethical Standards

Conflict of Interest

Jordan E. Ezekian declares no conflict of interest.

Kevin D. Hill reports another from Actelion (he is a site PI for a multicenter trial of macitentan for treatment of PAH in children).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart. 2009;95(4):312–7.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755–64.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    van Loon RL, Roofthooft MT, Delhaas T, van Osch-Gevers M, ten Harkel AD, Strengers JL, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol. 2010;106(1):117–24.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension. Circulation. 2012;125(1):113–22.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914–23.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Lau EM, Tamura Y, McGoon MD, Sitbon O. The 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J. 2015;46(4):879–82.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    •• Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037–99 These represent the first consensus guidelines specifically focused on diagnosis and management of pediatric pulmonary hypertension from the American Heart Association and American Thoracic Society.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol. 2004;38(1):2–22.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Lammers AE, Adatia I, Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, et al. Functional classification of pulmonary hypertension in children: report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ. 2011;1(2):280–5.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    E Hatano, T. Strasser. Primary pulmonary hypertension: report on a WHO meeting, Geneva, 15–17 October, 1973. Geneva: World Health Organization; 1975. 1975.Google Scholar
  14. 14.
    S Rich, LJ Rubin, Abenhail L Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6–10, 1998). . 1998.Google Scholar
  15. 15.
    Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S–12S.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):S43–54.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D117–26.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    •• Zijlstra WM, Douwes JM, Ploegstra MJ, Krishnan U, Roofthooft MT, Hillege HL, et al. Clinical classification in pediatric pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ. 2016;6(3):302–12 Findings from this study suggest that the NICE CHD classification is applicable to patients with specific groups of CHD but highlights limitations of the classification system as some patients are unable to be classified based on the current criteria.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286–98.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease--the need for refinement of the Evian-Venice classification. Cardiol Young. 2008;18(1):10–7.PubMedPubMedCentralGoogle Scholar
  21. 21.
    van Loon RLE, Roofthooft MTR, van Osch-Gevers M, Delhaas T, Strengers JLM, Blom NA, et al. Clinical characterization of pediatric pulmonary hypertension- complex presentation and diagnosis. J Pediatr. 2009;155:176–82.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart--cleaning up a dog’s dinner. Cardiol Young. 2008;18(1):22–5.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Pasquali SK, Hall M, Slonim AD, Jenkins KJ, Marino BS, Cohen MS, et al. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes. 2008;1(2):74–83.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Antosova M, Mokra D, Pepucha L, Plevkova J, Buday T, Sterusky M, et al. Physiology of nitric oxide in the respiratory system. Physiol Res 2017;66 (Suppl. 2):S159-SS72.Google Scholar
  25. 25.
    Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(6):639–46.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342:469–74.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Barst RJ, Channick R, Ivy D, Goldstein B. Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Pulm Circ. 2012;2(2):139–47.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol. 1999;33(3):813–9.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract. 2014;2014(3):257–90.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105–13.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Huddleston AJ, Knoderer CA, Morris JL, Ebenroth ES. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol. 2009;30(7):871–82.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Hill KD, Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, et al. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med. 2013;14(6):593–600.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29(13):1681–7.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Sabri MR, Zolfi-Gol A, Ahmadi A, Haghjooy-Javanmard S. Effect of tadalafil on myocardial and endothelial function and exercise performance after modified Fontan operation. Pediatr Cardiol. 2016;37(1):55–61.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123(11):1185–93.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Garcia AM, Nakano SJ, Karimpour-Fard A, Nunley K, Blain-Nelson P, Stafford NM, et al. Phosphodiesterase-5 is elevated in failing single ventricle myocardium and affects cardiomyocyte remodeling in vitro. Circ Heart Fail. 2018;11(9):e004571.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324–34.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, et al. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med. 2013;187(6):572–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011;37(3):502–9.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Kipfmueller F, Schroeder L, Berg C, Heindel K, Bartmann P, Mueller A. Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia. Pediatr Pulmonol. 2018;53(4):452–60.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Darland LK, Dinh KL, Kim S, Placencia JL, Varghese NP, Ruiz F, et al. Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. Pediatr Pulmonol. 2017;52(2):232–7.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280–8.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Goldberg DJ, Zak V, Goldstein BH, McCrindle BW, Menon SC, Schumacher KR, et al. Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. Am Heart J. 2018;201:1–8.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol. 2002;53:215–305.Google Scholar
  45. 45.
    Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353(9147):133–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358(9288):1119–23.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    A study to assess whether macitentan delays disease progression in children with pulmonary arterial hypertension (PAH) (TOMORROW) 2017 [NCT02932410]. Available from: https://clinicaltrials.gov/ct2/show/NCT02932410.
  50. 50.
    Barst RJ, Rubin LJ, WAea L. A comparison of continuous intravenouse epoprostenol (prostacyclin) with conventional therapy for pulmonary hypertension. N Engl J Med. 1996;334:296–301.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409–15.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart. 2007;93(6):739–43.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol. 2008;129(3):333–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(2):161–9.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Ablonczy L, Tordas D, Kis E, Szatmari A. Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension-bridge-to-transplant or long-term treatment? Pediatr Transplant. 2018;22(2).CrossRefGoogle Scholar
  56. 56•.
    . Coons JC, Miller T. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience. Ther Adv Respir Dis. 2018;12:1753466618766490 This review reports the evidence for and use of treprostinil, the first oral prostacyclin approved for treatment of PAH.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Lawrence KM, Hedrick HL, Monk HM, Herkert L, Waqar LN, Hanna BD, et al. Treprostinil improves persistent pulmonary hypertension associated with congenital diaphragmatic hernia. J Pediatr. 2018;200:44–9.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol. 2003;41:908–15.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–29.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of Pediatric CardiologyDuke University Medical CenterDurhamUSA

Personalised recommendations